These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38619037)

  • 21. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
    BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
    Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
    J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
    Confavreux C; Li DK; Freedman MS; Truffinet P; Benzerdjeb H; Wang D; Bar-Or A; Traboulsee AL; Reiman LE; O'Connor PW;
    Mult Scler; 2012 Sep; 18(9):1278-89. PubMed ID: 22307384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Williams MJ; Amezcua L; Cohan SL; Cohen JA; Delgado SR; Hua LH; Lucassen EB; Piccolo RS; Koulouris CR; Stankiewicz J
    Neurology; 2024 Aug; 103(3):e209610. PubMed ID: 39018512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
    Lebrun-Frénay C; Siva A; Sormani MP; Landes-Chateau C; Mondot L; Bovis F; Vermersch P; Papeix C; Thouvenot E; Labauge P; Durand-Dubief F; Efendi H; Le Page E; Terzi M; Derache N; Bourre B; Hoepner R; Karabudak R; De Seze J; Ciron J; Clavelou P; Wiertlewski S; Turan OF; Yucear N; Cohen M; Azevedo C; Kantarci OH; Okuda DT; Pelletier D;
    JAMA Neurol; 2023 Oct; 80(10):1080-1088. PubMed ID: 37603328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials.
    Xu M; Lu X; Fang J; Zhu X; Wang J
    J Clin Neurosci; 2016 Nov; 33():28-31. PubMed ID: 27492048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
    Front Immunol; 2021; 12():730342. PubMed ID: 34721394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
    J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
    J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
    Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
    Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Sprenger T; Kappos L; Sormani MP; Miller AE; Poole EM; Cavalier S; Wuerfel J
    Mult Scler; 2022 Oct; 28(11):1719-1728. PubMed ID: 35485424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
    Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS
    Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated review of teriflunomide's use in multiple sclerosis.
    Miller AE
    Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teriflunomide: Pediatric First Approval.
    Paik J
    Paediatr Drugs; 2021 Nov; 23(6):609-613. PubMed ID: 34595696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.